GLP-1 Receptor Agonists Show Promise for Preventing Stroke

Stroke remains a leading cause of death and long-term disability globally, often linked to cardiovascular risk factors like type 2 diabetes and obesity. While current preventative strategies exist, there's a critical need for novel therapeutic approaches that address the underlying pathophysiology. This review specifically examines the emerging role of GLP-1 receptor agonists (GLP-1RAs) in mitigating stroke risk and improving outcomes.

The review consistently highlighted that GLP-1RAs exert beneficial effects beyond glycemic control, including cardiovascular protection and neuroprotective properties. These agents were found to improve endothelial function (the health of blood vessel linings), reduce inflammation, decrease oxidative stress, and lower blood pressure, all factors crucial in stroke pathogenesis. They also demonstrated potential in reducing atherosclerosis (hardening of arteries) progression and improving cerebral blood flow. The most significant finding was the consistent evidence suggesting that GLP-1RAs may directly reduce the incidence of both ischemic and hemorrhagic stroke, largely through their multifaceted cardiovascular and anti-inflammatory actions. Furthermore, some studies indicated a potential for neurogenesis (new neuron formation) and synaptic plasticity (brain's ability to reorganize connections) enhancement post-stroke in preclinical models, suggesting a role in recovery.